WAT

Waters Corporation (WAT) - Q2 2006 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended July 1, 2006, and the six-month period ended on the same date. Waters Corporation designs, manufactures, and services analytical instrument systems, primarily High Performance Liquid Chromatography (HPLC), Ultra Performance Liquid Chromatography (UPLC), and Mass Spectrometry (MS) instruments, as well as thermal analysis and rheometry instruments. The company operates through two divisions: Waters Division and TA Instruments Division.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 6% for the quarter and 7% for the six-month period compared to the prior year. Growth was driven by new product initiatives (ACQUITY UPLC, Q-Tof Premier, Quattro Premier XE) and strong demand in Asia (India and China growth >50%).
• Profitability Decline: Operating income decreased $4.1 million for the quarter and $2.4 million for the six-month period. This decline occurred despite revenue growth and was primarily due to the adoption of SFAS No. 123(R) (adding $6.5 million and $13.9 million in stock-based compensation costs, respectively) and restructuring charges of $3.0 million and $7.3 million.
• Margin Compression: Gross profit margin decreased slightly to 58.3% from 58.9% (quarter) and 58.6% (six-month) due to the mix of lower-margin ACQUITY UPLC sales and the ramp-up of Alliance production outsourcing in Singapore.
• Interest Expense: Interest expense more than doubled for the quarter ($12.5 million vs. $5.8 million) due to increased borrowings to fund share repurchases and higher interest rates.

Guidance, Outlook, and Risks

• Outlook: Management anticipates continued positive growth in industrial and food safety markets but remains cautious regarding pharmaceutical spending from large U.S. customers. The VICAM acquisition is expected to add approximately $8.0 million to sales in 2006.
• Restructuring: A cost reduction plan initiated in February 2006 involved terminating 74 employees and closing a Netherlands office. The company expects to incur an additional $0.5 million to $1.0 million in restructuring costs for the remainder of 2006, with anticipated annual savings of $7.1 million thereafter.
• Stock-Based Compensation: The company expects full-year 2006 pre-tax stock-based compensation expense to be approximately $30.0 million.
• Liquidity: The company maintains a $500 million share repurchase program, with $114 million remaining authorized as of July 1, 2006. Management believes current cash and debt levels provide adequate financial flexibility.
• Risks: Key risks include reliance on pharmaceutical industry spending (approx. 51% of sales), foreign currency fluctuations (70% of sales outside U.S.), and ongoing patent litigation (notably with Agilent/HP, partially settled in Feb 2006 for £3.5 million).

Investor Verification Checklist

• Pharma Exposure: Verify the specific impact of weak demand from large U.S. pharmaceutical customers on future quarters.
• Restructuring Savings: Monitor the realization of the projected $7.1 million in annual cost savings from the 2006 restructuring initiative.
• Inventory Levels: Review the $29.1 million increase in inventory over six months to ensure it aligns with new product ramp-ups and does not signal future write-downs.
• Debt Servicing: Assess the impact of rising interest rates on the $845 million debt load and future interest expense.
• Legal Contingencies: Track the status of remaining patent litigation in France and Germany regarding the Alliance pump.